Company intelligence / Profile preview
UbiVac
Portland, Oregon, United Statesubivac.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
DPV-001 (lead product) has induced and/or boosted immune response in every patient evaluated to date (AACR 2024). Early data shows tripling or more of response rate in HNSCC patients receiving DPV-001 as part of combination immunotherapy.
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic immune activatorsVaccinesCellular immunotherapies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
National Cancer Institute (supporting clinical trial)
Beyond the preview
Go deeper on UbiVac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UbiVac.